Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H; EXAFIP investigators and the OrphaLung network. Naccache JM, et al. Among authors: gibelin a. Lancet Respir Med. 2022 Jan;10(1):26-34. doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 7. Lancet Respir Med. 2022. PMID: 34506761 Clinical Trial.
Non-invasive ventilation versus high-flow nasal cannula oxygen therapy with apnoeic oxygenation for preoxygenation before intubation of patients with acute hypoxaemic respiratory failure: a randomised, multicentre, open-label trial.
Frat JP, Ricard JD, Quenot JP, Pichon N, Demoule A, Forel JM, Mira JP, Coudroy R, Berquier G, Voisin B, Colin G, Pons B, Danin PE, Devaquet J, Prat G, Clere-Jehl R, Petitpas F, Vivier E, Razazi K, Nay MA, Souday V, Dellamonica J, Argaud L, Ehrmann S, Gibelin A, Girault C, Andreu P, Vignon P, Dangers L, Ragot S, Thille AW; FLORALI-2 study group; REVA network. Frat JP, et al. Among authors: gibelin a. Lancet Respir Med. 2019 Apr;7(4):303-312. doi: 10.1016/S2213-2600(19)30048-7. Epub 2019 Mar 18. Lancet Respir Med. 2019. PMID: 30898520 Clinical Trial.
Alveolar lymphocytosis with plasmacytosis in severe COVID-19.
Voiriot G, Fajac A, Gibelin A, Parrot A, Fartoukh M. Voiriot G, et al. Among authors: gibelin a. Respir Med Res. 2020 Nov;78:100784. doi: 10.1016/j.resmer.2020.100784. Epub 2020 Aug 14. Respir Med Res. 2020. PMID: 32866717 Free PMC article. No abstract available.
Randomised trial of first-line bronchial artery embolisation for non-severe haemoptysis of mild abundance.
Fartoukh M, Demoule A, Sanchez O, Tuffet S, Bergot E, Godet C, Andrejak C, Pontier-Marchandise S, Parrot A, Mayaux J, Meyer G, Cluzel P, Sapoval M, Le Pennec V, Carette MF, Cadranel J, Rousseau A, Khalil A, Simon T; ARTEMHYS trial group. Fartoukh M, et al. BMJ Open Respir Res. 2021 Jun;8(1):e000949. doi: 10.1136/bmjresp-2021-000949. BMJ Open Respir Res. 2021. PMID: 34088727 Free PMC article. Clinical Trial.
Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients.
Voiriot G, Dorgham K, Bachelot G, Fajac A, Morand-Joubert L, Parizot C, Gerotziafas G, Farabos D, Trugnan G, Eguether T, Blayau C, Djibré M, Elabbadi A, Gibelin A, Labbé V, Parrot A, Turpin M, Cadranel J, Gorochov G, Fartoukh M, Lamazière A. Voiriot G, et al. Among authors: gibelin a. Sci Rep. 2022 Jun 9;12(1):9502. doi: 10.1038/s41598-022-13179-0. Sci Rep. 2022. PMID: 35681070 Free PMC article.
50 results